Edgewise Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 88
- Market Cap
- -
- Website
- http://www.edgewisetx.com
- Introduction
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT06916897
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06738836
- Locations
- 🇺🇸
Pharmaron Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06347159
- Locations
- 🇺🇸
Morristown Medical Center (Atlantic Health System), Morristown, New Jersey, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Stanford University Hospital / Stanford Health Care, Stanford, California, United States
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: Sevasemten Dose 3Drug: Sevasemten Dose 1Drug: Sevasemten Dose 2Drug: Placebo
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT06100887
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT06066580
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸UC San Diego, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Study of EDG-7500 in Healthy Adults
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT06011317
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
- Conditions
- Genetic Diseases, InbornMuscular DystrophiesHealthy VolunteerMuscular Disorders, AtrophicMusculoskeletal DiseasesNeuromuscular DiseasesMuscular DiseasesNervous System Diseases
- Interventions
- Drug: Radiolabeled EDG-5506 SuspensionDrug: EDG-5506 TabletDrug: Radiolabeled EDG-5506 Intravenous
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05730842
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: Sevasemten Dose 2Drug: Sevasemten Dose 3Drug: Sevasemten Dose 4Drug: Sevasemten Dose 5Drug: Sevasemten Dose 1Drug: Placebo
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT05540860
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05492734
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Drug: Sevasemten 10 mgDrug: Sevasemten 5 mgDrug: Sevasemten 12.5 mgDrug: Placebo
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Edgewise Therapeutics, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT05291091
- Locations
- 🇺🇸
UC Denver, Aurora, Colorado, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Rare Disease Research, Atlanta, Georgia, United States